Ellomay Capital Ltd. (NYSE:ELLO)

ELLOMAY CAPITAL (formerly NUR Macroprinters Ltd.) and a former leading supplier of wide-format inkjet production printers for the printing industry, consummated the sale of its business to Hewlett-Packard Company on February 29, 2008.

Ellomay Capital Ltd. (NYSE:ELLO)’s Financial Overview

Ellomay Capital Ltd. (NYSE) declined -3.48% yesterday to close its trading session at $8.79. The company has 1 year Price Target of $11.3. Ellomay Capital Ltd. has 52-Week high of $9.7 and 52-Week Low of $7.4. The stock touched its 52-Week High on 9.70 and 52-Week Low on 7.40. The stock traded with the volume of 1 shares yesterday. The firm shows the market capitalization of $89.22 Million.

The firm is trading with SMA20 of 3.33 Percent, SMA50 of 5.42 Percent and SMA200 of 4.66 percent. Ellomay Capital Ltd. has P/S value of 5.25 while its P/B value stands at 1.08. Similarly, the company has Return on Assets of -1.2 percent, Return on Equity of -3.1 percent and Return on Investment of 1.4 Percent. The company shows Gross Margin and Operating Margin of 37.5 percent and 12.5 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 1 analysts offering 12-month price forecasts for Ellomay Capital Ltd have a median target of 52.00, with a high estimate of 52.00 and a low estimate of 52.00. The median estimate represents a +471.01% increase from the last price of 9.11.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)

Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York.

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)’s Financial Outlook

There is no forecast data available.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

The Stock declined -22.74% and closed its last trading session at $2.14. The company has the market capitalization of $7.79 Million. The stock has 52-week high of $6.6 and 52-Week low of $1.6. The firm touched its 52-Week high on 6.60 and 52-Week low on 1.58. The company has volume of 334328 shares. The company has a total of 3.64 Million shares outstanding.

Ohr Pharmaceutical, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.05/share where the analyst estimated EPS was $-0.07/share. The difference between the actual and Estimated EPS is $0.02. This shows a surprise factor of 28.6 percent.

The company has YTD performance of 24.42 percent. Beta for Ohr Pharmaceutical, Inc. stands at 1.26 while its ATR (average true range) is 0.53. The company has Weekly Volatility of 39.03%% and Monthly Volatility of 18.94%%.

Ohr Pharmaceutical, Inc. has distance from 20-day Simple Moving Average (SMA20) of -12.06%, Distance from 50-Day Simple Moving Average of -16.2 percent and Distance from 200-Day Simple Moving Average of -41.94%.

The Company currently has ROA (Return on Assets) of -73 percent, Return on Equity (ROE) of -80.9 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *